Saturday 17 October 2026
Export BIIB’s income statement to Excel — free account
Biogen Inc.
BIIB Healthcare Drug Manufacturers General
Biogen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.9 billion, up 2.22% from fiscal 2024. In the quarter to June 2026, revenue grew 3.42%, EPS fell 84.8%, free cash flow grew 103.3% and total debt rose 16.0%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
232.65
2.70
−1.15%
Follow BIIB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
38.04 | 19.61 | 19.93 | 12.75 |
+8 more quarters Free account |
P/S ratio |
3.18 | 2.72 | 2.61 | 2.04 | |
P/FCF ratio |
12.56 | 11.24 | 12.77 | 9.08 | |
P/Operating CF |
71.09 | 41.81 | 50.37 | 16.14 | |
P/B ratio |
1.69 | 1.45 | 1.41 | 1.13 | |
Price to Tangible BV |
0.00 | 8.68 | 9.97 | 8.61 | |
EV/Sales |
3.78 | 2.92 | 2.86 | 2.27 | |
EV/EBITDA |
14.71 | 9.57 | 9.62 | 7.23 | |
EV/Operating CF |
13.17 | 11.19 | 12.82 | 9.32 | |
EV/FCF |
14.93 | 12.07 | 13.99 | 10.11 | |
Quick Ratio |
0.81 | 1.88 | 1.54 | 1.62 | |
Current Ratio |
1.87 | 3.06 | 2.68 | 2.72 | |
Net Debt/EBITDA |
10.18 | 2.83 | 5.84 | 2.72 | |
Debt/Assets |
22.72% | 21.33% | 21.35% | 21.52% | |
Debt/Equity |
0.39 | 0.34 | 0.34 | 0.35 | |
Asset Turnover |
0.33 | 0.35 | 0.34 | 0.35 | |
Operating CF/Net income |
4.60 | 2.02 | (10.47) | 2.73 | |
Capex/Depreciation |
(0.40) | (0.16) | (0.19) | (0.20) | |
Research and Development Expense of Revenue |
19.36% | 21.75% | 22.35% | 17.21% | |
Selling, General and Administrative Expense of Revenue |
25.94% | 24.51% | 29.94% | 23.47% | |
Intangible Assets out of Total Assets |
0.64 | 0.53 | 0.53 | 0.54 | |
Share Based Compensation of Revenue |
2.83% | 3.39% | 2.61% | 2.97% | |
Graham Net Nets |
(0.19) | (0.06) | (0.09) | (0.10) | |
Graham Number |
127.71 | 163.27 | 157.35 | 175.25 | |
Earnings Yield |
2.63% | 5.10% | 5.02% | 7.85% | |
Free Cash Flow Yield |
7.96% | 8.90% | 7.83% | 11.02% | |
Revenue per Share |
18.52 | 16.83 | 15.56 | 17.29 | |
Operating CF per Share |
3.04 | 4.39 | 3.49 | 8.68 | |
Capex per Share |
(1.19) | (0.35) | (0.41) | (0.35) | |
Free Cash Flow per Share |
1.85 | 4.04 | 3.08 | 8.33 | |
Cash per Share |
8.70 | 29.09 | 26.05 | 27.02 | |
Shareholders Equity per Share |
127.61 | 126.71 | 124.62 | 124.20 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
127.61 | 126.71 | 124.62 | 124.20 | |
Free Cash Flow |
273.00 | 594.30 | 451.70 | 1,221.00 | |
Working Capital |
3,388.60 | 6,191.50 | 5,624.70 | 5,646.60 | |
Capital Expenditures |
(175.90) | (51.20) | (60.20) | (51.50) | |
Net Current Asset Value |
(5,932.90) | (1,641.00) | (2,208.60) | (2,063.40) | |
EV/EBIT |
30.63 | 15.42 | 15.17 | 10.37 | |
Capex to Sales |
0.06 | 0.02 | 0.03 | 0.02 | |
Price to Operating Income |
25.78 | 14.36 | 13.85 | 9.31 | |
| Other line items | |||||
Average Receivables |
1,754.90 | 1,682.85 | 1,373.60 | 1,455.15 | |
Average Payables |
406.15 | 375.00 | 428.10 | 417.90 | |
Average Inventory |
2,329.30 | 2,111.45 | 2,314.30 | 2,339.30 | |
Average Assets |
30,208.40 | 28,758.10 | 28,744.40 | 28,760.35 | |
Average Common Equity |
18,241.00 | 17,815.20 | 17,486.40 | 17,283.20 |
Columns are period end dates